How do you view the use of adjuvant CDK4/6 inhibitors overall given discordant results between MonarchE and PALLAS?  

Are there factors to explain why MonarchE was a positive study and PALLAS was not? 



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice